Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourDescending Triangle
15 minLeaning Bearish
5 minBullish
Daily trend turns up above $19.26
Key levels
Resistance$31.66
Resistance$29.89
Support$27.46
Support$24.50
Latest news & SEC filings
SEC FilingEnovis CORP filed an insider trading report (Form 4)
AnalystCanaccord Genuity keeps Buy rating on Enovis, cuts price target to $42
AnalystWells Fargo keeps Overweight rating on Enovis, lifts target to $37
All ENOV news →Enovis is a medical technology company that develops and sells devices used in orthopedic care, from injury prevention through joint replacement to recovery afterward. It runs two segments: Prevention & Recovery, which makes braces, thermal therapy products, bone growth stimulators, compression garments, and electrical stimulation devices; and Reconstructive, which supplies implants, instruments, and supporting technology for joint replacement and limb procedures. Its customers include surgeons, healthcare systems, therapists, and other professionals, and it sells across the United States, Europe, and the Asia-Pacific region.
Based on the company's 10-K filed Feb 26, 2026.
NYSE · Healthcare
SEPT Low Target
$29.00
SEPT Mid Target
$38.00
SEPT High Target
$47.00
Analyst Consensus
$38.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ENOV.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$46.73
30
Moat Score
NONE
4/9
Piotroski Score
-0.3
Altman Z-Score
Insider Signal
BUYING
6 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Wienbar Sharon L | director | Buy | 924 | $25K | Nov 9, 2026 |
| Wienbar Sharon L | director | Buy | 907 | $25K | Nov 6, 2026 |
| Ortiz Christine | director | Buy | 958 | - | Sep 30, 2026 |
| Engert Oliver | officer | Buy | 200 | $4K | Jun 11, 2026 |
| Engert Oliver | officer | Buy | 1,000 | $22K | Jun 11, 2026 |
| Engert Oliver | officer | Buy | 1,000 | $23K | Jun 10, 2026 |
| Engert Oliver | officer | Buy | 1,000 | $22K | Jun 1, 2026 |
| Shirley Brady | director | Buy | 9,346 | - | May 19, 2026 |
| Bodem Barbara W. | director | Buy | 9,346 | - | May 19, 2026 |
| Okala Philip | director | Buy | 9,346 | - | May 19, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
6.7%
3yr Revenue CAGR
12.9%
EPS Growth YoY
-38.98%
FCF Growth YoY
129.6%
Revenue Trend
STABLE
SEPT Investing tracks real-time dark pool institutional trades for ENOV, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:45 | $28.55 | 25,275 | $$722K | SELL |
| 21:00:38 | $28.55 | 2,544 | $$73K | SELL |
| 21:00:38 | $28.55 | 1,588 | $$45K | SELL |
| 21:00:37 | $28.55 | 18,100 | $$517K | SELL |
| 21:00:37 | $28.55 | 1,100 | $$31K | SELL |
5 dark pool trades shown · $$1.4M preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for ENOV, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $30 | Nov 20 | 9 | $$85 | 1 | SWEEP |
| CALL | $30 | Nov 20 | 9 | $$85 | 1 | SWEEP |
| CALL | $30 | Nov 20 | 9 | $$85 | 1 | SWEEP |
| CALL | $30 | Nov 20 | 9 | $$2890 | 34 | SWEEP |
| CALL | $30 | Nov 20 | 9 | $$425 | 5 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Enovis CORP (ENOV) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Enovis CORP (ENOV) is at $28.55, up 1.17% (+$0.33) at the Nov 11, 2026 close.
Latest ENOV news — Nov 10, 2026: Enovis CORP filed an insider trading report (Form 4) · Nov 6, 2026: Canaccord Genuity keeps Buy rating on Enovis, cuts price target to $42
The average analyst price target for ENOV is $38.00, ranging from $29 to $47, based on 9 analysts. Latest: Canaccord Genuity maintains on Nov 6, 2026.
Analyst ratings for ENOV: 1 Buy, 18 Hold, 0 Sell — consensus Hold.
ENOV last reported on Nov 5, 2026: EPS $0.88 vs $0.77 expected — a beat of 14.7%.
ENOV does not currently pay a dividend.
Enovis CORP reported $1.3B of debt and $13M of cash (Oct 2, 2026).
Support: $27.46, $24.50, $22.71. Resistance: $29.89, $31.66, $34.28.
Insider activity: BUYING, 6 buys and 0 sells in the last 90 days.
Nov 10, 2026: Enovis CORP filed an insider trading report (Form 4) · Nov 6, 2026: Canaccord Genuity keeps Buy rating on Enovis, cuts price target to $42 · Nov 6, 2026: Wells Fargo keeps Overweight rating on Enovis, lifts target to $37